Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer

Uterine cervical cancer is one of the leading causes of cancer-related mortality in women worldwide. Each year, over half a million new cases are estimated, resulting in more than 300,000 deaths. While less-invasive, fertility-preserving surgical procedures can be offered to women in early stages, t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maximilian Fleischmann, Georgios Chatzikonstantinou, Emmanouil Fokas, Jörn Wichmann, Hans Christiansen, Klaus Strebhardt, Claus Rödel, Nikolaos Tselis, Franz Rödel
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	cervical cancer predictive prognostic molecular marker biomarker outcome Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a1a25d87ef9f46f1a1e8ad9cd3d0d1ba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a1a25d87ef9f46f1a1e8ad9cd3d0d1ba
record_format	dspace
spelling	oai:doaj.org-article:a1a25d87ef9f46f1a1e8ad9cd3d0d1ba2021-11-25T17:03:33ZMolecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer10.3390/cancers132257482072-6694https://doaj.org/article/a1a25d87ef9f46f1a1e8ad9cd3d0d1ba2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5748https://doaj.org/toc/2072-6694Uterine cervical cancer is one of the leading causes of cancer-related mortality in women worldwide. Each year, over half a million new cases are estimated, resulting in more than 300,000 deaths. While less-invasive, fertility-preserving surgical procedures can be offered to women in early stages, treatment for locally advanced disease may include radical hysterectomy, primary chemoradiotherapy (CRT) or a combination of these modalities. Concurrent platinum-based chemoradiotherapy regimens remain the first-line treatments for locally advanced cervical cancer. Despite achievements such as the introduction of angiogenesis inhibitors, and more recently immunotherapies, the overall survival of women with persistent, recurrent or metastatic disease has not been extended significantly in the last decades. Furthermore, a broad spectrum of molecular markers to predict therapy response and survival and to identify patients with high- and low-risk constellations is missing. Implementation of these markers, however, may help to further improve treatment and to develop new targeted therapies. This review aims to provide comprehensive insights into the complex mechanisms of cervical cancer pathogenesis within the context of molecular markers for predicting treatment response and prognosis.Maximilian FleischmannGeorgios ChatzikonstantinouEmmanouil FokasJörn WichmannHans ChristiansenKlaus StrebhardtClaus RödelNikolaos TselisFranz RödelMDPI AGarticlecervical cancerpredictiveprognosticmolecular markerbiomarkeroutcomeNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5748, p 5748 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cervical cancer predictive prognostic molecular marker biomarker outcome Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cervical cancer predictive prognostic molecular marker biomarker outcome Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Maximilian Fleischmann Georgios Chatzikonstantinou Emmanouil Fokas Jörn Wichmann Hans Christiansen Klaus Strebhardt Claus Rödel Nikolaos Tselis Franz Rödel Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
description	Uterine cervical cancer is one of the leading causes of cancer-related mortality in women worldwide. Each year, over half a million new cases are estimated, resulting in more than 300,000 deaths. While less-invasive, fertility-preserving surgical procedures can be offered to women in early stages, treatment for locally advanced disease may include radical hysterectomy, primary chemoradiotherapy (CRT) or a combination of these modalities. Concurrent platinum-based chemoradiotherapy regimens remain the first-line treatments for locally advanced cervical cancer. Despite achievements such as the introduction of angiogenesis inhibitors, and more recently immunotherapies, the overall survival of women with persistent, recurrent or metastatic disease has not been extended significantly in the last decades. Furthermore, a broad spectrum of molecular markers to predict therapy response and survival and to identify patients with high- and low-risk constellations is missing. Implementation of these markers, however, may help to further improve treatment and to develop new targeted therapies. This review aims to provide comprehensive insights into the complex mechanisms of cervical cancer pathogenesis within the context of molecular markers for predicting treatment response and prognosis.
format	article
author	Maximilian Fleischmann Georgios Chatzikonstantinou Emmanouil Fokas Jörn Wichmann Hans Christiansen Klaus Strebhardt Claus Rödel Nikolaos Tselis Franz Rödel
author_facet	Maximilian Fleischmann Georgios Chatzikonstantinou Emmanouil Fokas Jörn Wichmann Hans Christiansen Klaus Strebhardt Claus Rödel Nikolaos Tselis Franz Rödel
author_sort	Maximilian Fleischmann
title	Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
title_short	Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
title_full	Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
title_fullStr	Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
title_full_unstemmed	Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
title_sort	molecular markers to predict prognosis and treatment response in uterine cervical cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a1a25d87ef9f46f1a1e8ad9cd3d0d1ba
work_keys_str_mv	AT maximilianfleischmann molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT georgioschatzikonstantinou molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT emmanouilfokas molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT jornwichmann molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT hanschristiansen molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT klausstrebhardt molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT clausrodel molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT nikolaostselis molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT franzrodel molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer
_version_	1718412793172983808

Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer

Ejemplares similares